We last featured thyroid eye disease in our June 10, 2021, issue of Healio | OSN. Interested readers might enjoy reviewing that cover story and my perspective.
We have learned much about thyroid eye disease (TED) in the last 2 years. In this commentary, I will focus my comments on diagnosis and medical therapy, especially with Tepezza (teprotumumab-trbw, Horizon Therapeutics/now Amgen).
Thyroid eye disease was first described by Robert Graves, an Irish physician who recognized the association of hyperthyroidism and exophthalmos in 1835, so it is special that an Irish (Read more...)